Clinical trials: BRCA Mutation
Early Breast Cancer
Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
A PHASE 2, NON RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER
- Trial name
- NCT03499353
- Testing
- TALAZOPARIB
- Where
- 97 sites in United States
- Volunteers
- 61 people
- Sponsor
- Pfizer
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or…
- Trial name
- NCT02983799
- Testing
- OLAPARIB
- Where
- 47 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- AstraZeneca
Breast Cancer
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
This trial will evaluate the use of immunotherapy and PARP inhibition in a population with incurable advanced breast cancer associated with a germline BRCA mutation or HDR-defect.
- Trial name
- NCT03025035
- Testing
- Pembrolizumab, Olaparib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Yuan Yuan
Ovarian Cancer, Primary Peritoneal Cancer
Phase II ABT-888 With Cyclophosphamide
Background: The experimental cancer treatment drug ABT-888 (Veliparib) works by preventing deoxyribonucleic acid (DNA) repair in tumor cells.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer
- Trial name
- NCT01306032
- Testing
- ABT-888, Cyclophosphamide
- Where
- 10 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)